
浏览全部资源
扫码关注微信
1.陆军特色医学中心(第三军医大学大坪医院):,消化内科,消化系统肿瘤精准防治重庆市重点实验室,重庆
2.陆军特色医学中心(第三军医大学大坪医院):,病理科,重庆
3.重庆医科大学第一临床学院,重庆
王 涛,E-mail: t26983@tmmu.edu.cn
收稿日期:2024-09-27,
修回日期:2024-12-27,
纸质出版日期:2025-03-15
移动端阅览
郑喜鹏,潘惠琳,吴林育,等.内镜下LCPL征象对胃黏膜高危肠上皮化生的诊断价值[J].陆军军医大学学报,2025,47(05):407-416.DOI:10.16016/j.2097-0927.202409149.
ZHENG X P,PAN H L,WU L Y,et al.Diagnostic value of endoscopic LCPL sign for high-risk intestinal metaplasia in gastric mucosa[J].J Army Med Univ,2025,47(05):407-416.DOI:10.16016/j.2097-0927.202409149.
郑喜鹏,潘惠琳,吴林育,等.内镜下LCPL征象对胃黏膜高危肠上皮化生的诊断价值[J].陆军军医大学学报,2025,47(05):407-416.DOI:10.16016/j.2097-0927.202409149. DOI:
ZHENG X P,PAN H L,WU L Y,et al.Diagnostic value of endoscopic LCPL sign for high-risk intestinal metaplasia in gastric mucosa[J].J Army Med Univ,2025,47(05):407-416.DOI:10.16016/j.2097-0927.202409149. DOI:
目的
2
探讨内镜下亮蓝嵴(light blue crest, LBC)包绕的乳头状区域(LBC capsuling papillary lesion, LCPL)征象在高危胃黏膜肠上皮化生(intestinal metaplasia,IM,简称“肠化”)中的诊断价值。
方法
2
选取2021年1月至2023年6月在陆军特色医学中心消化内科接受内镜检查及活检的314例患者(共352块活检样本)。采用HE染色及高铁二胺-阿尔新蓝(high iron diamine-alcian blue,HID-AB)染色(诊断高危肠化的金标准)检查样本的组织学类型及肠化类型,并据此将样本分为慢性炎症组、低危肠化组、高危肠化组、高-中分化肠型胃癌组、低分化肠型胃癌组。结合活检部位内镜下图像,统计分析LCPL在各组中的阳性率;采用Logistic回归分析LCPL征象与高危肠化的关系,以及与LCPL相关的临床病理特征;采用灵敏度、特异度、约登指数、受试者工作曲线下面积等指标,评价LCPL对高危肠化的诊断效能。
结果
2
LCPL征象在高危肠化组的阳性率达75.70%,显著高于其他各组(
P
均
<
0.001);Logistic回归分析显示LCPL与高危肠化密切相关(
OR=
30.286,95%
CI:
13.528~67.804,
P
<
0.001)。LCPL征象诊断高危肠化的灵敏度为69.84%、特异度为93.75%、约登指数为0.636、曲线下面积为0.818(95%
CI
:0.773~0.857);除灵敏度指标外,上述各诊断效能参数均显著优于诊断肠化与否的传统内镜下征象LBC(
P
均
<
0.001)。并且,LCPL征象的判别不易受到患者年龄(
OR=
1.130,95%
CI:
0.709~1.800,
P
=0.607)、病变部位(胃角:
OR=
2.360,95%
CI:
0.73
2~7.613,
P
=0.151;胃窦:
OR=
2.257,95%
CI:
0.756~6.744,
P
=0.145)、是否合并消化性溃疡(
OR=
1.085,95%
CI:
0.208~5.652,
P
=0.923)等因素的影响;94.12%的阳性、66.94%的阴性LCPL征象可在3 s内被快速识别(
OR=
4.536,95%
CI:
1.372~14.997,
P
=0.013)。
结论
2
内镜下LCPL征象在诊断胃黏膜高危肠化中有较好效能,具有潜在临床应用价值。
Objective To investigate the diagnostic value of endoscopic sign of light blue crest (LBC) capsuling papillary lesion (LCPL) for high-risk intestinal metaplasia (IM). Methods A total of 314 patients (352 biopsy specimens) who underwent endoscopic examination and biopsy in Department of Gastroenterology of Army Medical Center of PLA from January 2021 to June 2023 were recruited
and HE and HID-AB staining (the golden standard of high-risk IM) were apllied to detect the histological types and IM types. The samples were subsequently divided into chronic inflammation group
low-risk IM group
high-risk IM group
well-differentiated intestinal-type gastric cancer group
and poorly-differentiated intestinal-type gastric cancer group. The positive rate of LCPL in each group and its diagnostic efficacy were analyzed based on endoscopic images of the biopsy sites. Logistic regression analysis was used to investigate the relationship between LCPL sign and high-risk IM
as well as the clinical and pathological features associated with LCPL sign. Receiver operating characteristic (ROC) curve was plotted to evaluate the diagnostic efficacy of LCPL for high-risk IM
using indicators such as sensitivity
specificity
Youden index and area under the curve (AUC). Results The positive rate of the LCPL sign in high-risk IM group was 75.70%
significantly higher than that of the other groups (all
P
<
0.001). Logistic regression analysis showed that LCPL sign was significantly correlated with high-risk IM (
OR=
30.286
95%
CI:
13.528~67.804
P
<
0.001). When the sign was employed in diagnosing high-risk IM
the sensitivity was 69.84%
the specificity was 93.75%
the Youden’s index was 0.636
and the AUC value was 0.818 (95%
CI
: 0.773~0.857). Besides sensitivity
all above parameters of LCPL sign showed significantly better diagnostic efficacy than those of traditional LBC sign
which is used as a sign for diagnosing IM (
P
<
0.001). Moreover
recognition of LCPL sign was not easily affected by age (
OR=
1.130
95%
CI:
0.709~1.800
P
=0.607)
lesion site (Angular incisure:
OR=
2.360
95%
CI:
0.732~7.613
P
=0.151; Autrum:
OR=
2.257
95%
CI:
0.756~6.744
P
=0.145)
and presence of peptic ulcers (
OR=
1.085
95%
CI:
0.208~5.652
P
=0.923). Significantly
94.12% of positive and 66.94% of negative LCPL signs could be rapidly recognized within 3 s (
OR=
4.536
95%
CI:
1.372~14.997
P
=0.013). Conclusion LCPL sign shows high efficacy and potential clinical application value for high-risk IM in gastric mucosa of endoscopic diagnosis.
HAN B F , ZHENG R S , ZENG H M , et al . Cancer incidence and mortality in China, 2022 [J]. J Natl Cancer Cent , 2024 , 4 ( 1 ): 47 - 53 . DOI: 10.1016/j.jncc.2024.01.006 http://dx.doi.org/10.1016/j.jncc.2024.01.006 .
KATAI H , ISHIKAWA T , AKAZAWA K , et al . Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100 000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001-2007) [J]. Gastric Cancer , 2018 , 21 ( 1 ): 144 - 154 . DOI: 10.1007/s10120-017-0716-7 http://dx.doi.org/10.1007/s10120-017-0716-7 .
SUMIYAMA K . Past and current trends in endoscopic diagnosis for early stage gastric cancer in Japan [J]. Gastric Cancer , 2017 , 20 ( Suppl 1 ): 20 - 27 . DOI: 10.1007/s10120-016-0659-4 http://dx.doi.org/10.1007/s10120-016-0659-4 .
CORREA P . Human gastric carcinogenesis: a multistep and multifactorial process—First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention [J]. Cancer Res , 1992 , 52 ( 24 ): 6735 - 6740 .
HIGA J T , HWANG J H . Gastric intestinal metaplasia: an irreversible risk factor for gastric cancer? [J]. Gastrointest Endosc , 2016 , 84 ( 4 ): 625 - 627 . DOI: 10.1016/j.gie. 2016.04.028 http://dx.doi.org/10.1016/j.gie.2016.04.028 .
TAHARA T , TAHARA S , HORIGUCHI N , et al . Gastric mucosal microarchitectures associated with irreversibility with Helicobacter pylori eradication and downregulation of micro RNA (miR)-124a [J]. Cancer Invest , 2019 , 37 ( 9 ): 417 - 426 . DOI: 10.1080/07357907.2019.1663207 http://dx.doi.org/10.1080/07357907.2019.1663207 .
SHAH S C , GAWRON A J , MUSTAFA R A , et al . Histologic subtyping of gastric intestinal metaplasia: overview and considerations for clinical practice [J]. Gastroenterology , 2020 , 158 ( 3 ): 745 - 750 . DOI: 10.1053/j.gastro.2019.12.004 http://dx.doi.org/10.1053/j.gastro.2019.12.004 .
GOLDENRING J R , MILLS J C . Cellular plasticity, reprogramming, and regeneration: metaplasia in the stomach and beyond [J]. Gastroenterology , 2022 , 162 ( 2 ): 415 - 430 . DOI: 10.1053/j.gastro.2021.10.036 http://dx.doi.org/10.1053/j.gastro.2021.10.036 .
GIROUX V , RUSTGI A K . Metaplasia: tissue injury adaptation and a precursor to the dysplasia-cancer sequence [J]. Nat Rev Cancer , 2017 , 17 ( 10 ): 594 - 604 . DOI: 10.1038/nrc.2017.68 http://dx.doi.org/10.1038/nrc.2017.68 .
GUPTA S , LI D , EL SERAG H B , et al . AGA clinical practice guidelines on management of gastric intestinal metaplasia [J]. Gastroenterology , 2020 , 158 ( 3 ): 693 - 702 . DOI: 10.1053/j.gastro.2019.12.003 http://dx.doi.org/10.1053/j.gastro.2019.12.003 .
PIMENTEL-NUNES P , LIBÂNIO D , MARCOS-PINTO R , et al . Management of epithelial precancerous conditions and lesions in the stomach (MAPS Ⅱ): European Society of Gastroi ntestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019 [J]. Endoscopy , 2019 , 51 ( 4 ): 365 - 388 . DOI: 10.1055/a-0859-1883 http://dx.doi.org/10.1055/a-0859-1883 .
PIAZUELO M B , BRAVO L E , MERA R M , et al . The Colombian chemoprevention trial: 20-year follow-up of a cohort of patients with gastric precancerous lesions [J]. Gastroenterology , 2021 , 160 ( 4 ): 1106 - 1117.e3 . DOI: 10.1053/j.gastro.2020.11.017 http://dx.doi.org/10.1053/j.gastro.2020.11.017 .
GONZÁLEZ C A , SANZ-ANQUELA J M , GISBERT J P , et al . Utility of subtyping intestinal metaplasia as marker of gastric cancer risk. A review of the evidence [J]. Int J Cancer , 2013 , 133 ( 5 ): 1023 - 1032 . DOI: 10.1002/ijc.28003 http://dx.doi.org/10.1002/ijc.28003 .
UEDO N , ISHIHARA R , IISHI H , et al . A new method of diagnosing gastric intestinal metaplasia: narrow-band imaging with magnifying endoscopy [J]. Endoscopy , 2006 , 38 ( 8 ): 819 - 824 . DOI: 10.1055/s-2006-944632 http://dx.doi.org/10.1055/s-2006-944632 .
PIMENTEL-NUNES P , DINIS-RIBEIRO M , SOARES J B , et al . A multicenter validation of an endoscopic classification with narrow band imaging for gastric precancerous and cancerous lesions [J]. Endoscopy , 2012 , 44 ( 3 ): 236 - 246 . DOI: 10.1055/s-0031-1291537 http://dx.doi.org/10.1055/s-0031-1291537 .
KANZAKI H , UEDO N , ISHIHARA R , et al . Comprehensive investigation of areae gastricae pattern in gastric corpus using magnifying narrow band imaging endoscopy in patients with chronic atrophic fundic gastritis [J]. Helicobacter , 2012 , 17 ( 3 ): 224 - 231 . DOI: 10.1111/j.1523-5378.2012.00938.x http://dx.doi.org/10.1111/j.1523-5378.2012.00938.x .
KANEMITSU T , YAO K S , NAGAHAMA T , et al . Extending magnifying NBI diagnosis of intestinal metaplasia in the stomach: the white opaque substance marker [J]. Endoscopy , 2017 , 49 ( 6 ): 529 - 535 . DOI: 10.1055/s-0043-103409 http://dx.doi.org/10.1055/s-0043-103409 .
YAO K S , IWASHITA A , TANABE H , et al . White opaque substance within superficial elevated gastric neoplasia as visualized by magnification endoscopy with narrow-band imaging: a new optical sign for differentiating between adenoma and carcinoma [J]. Gastrointest Endosc , 2008 , 68 ( 3 ): 574 - 580 . DOI: 10.1016/j.gie.2008.04.011 http://dx.doi.org/10.1016/j.gie.2008.04.011 .
HAYEE B , INOUE H , SATO H , et al . Magnification narrow-band imaging for the diagnosis of early gastric cancer: a review of the Japanese literature for the western endoscopist [J]. Gastrointest Endosc , 2013 , 78 ( 3 ): 452 - 461 . DOI: 10.1016/j.gie.2013.03.1333 http://dx.doi.org/10.1016/j.gie.2013.03.1333 .
KANEMITSU T , UEDO N , ONO T , et al . Magnifying endoscopy with narrow-band imaging for diagnosis of subtype of gastric intestinal metaplasia [J]. J Gastroenterol Hepatol , 2023 , 38 ( 1 ): 94 - 102 . DOI: 10.1111/jgh.16034 http://dx.doi.org/10.1111/jgh.16034 .
WEI H F , LI W C , ZENG L L , et al . OLFM4 promotes the progression of intestinal metaplasia through activation of the MYH9/GSK3β/β-catenin pathway [J]. Mol Cancer , 2024 , 23 ( 1 ): 124 . DOI: 10.1186/s12943-024-02016-9 http://dx.doi.org/10.1186/s12943-024-02016-9 .
HANAHAN D . Hallmarks of cancer: new dimensions [J]. Cancer Discov , 2022 , 12 ( 1 ): 31 - 46 . DOI: 10.1158/2159-8290.CD-21-1059 http://dx.doi.org/10.1158/2159-8290.CD-21-1059 .
MAYER B , JOHNSON J P , LEITL F , et al . E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration [J]. Cancer Res , 1993 , 53 ( 7 ): 1690 - 1695 .
ZHANG Y J , WU X , ZHANG C L , et al . Dissecting expression profiles of gastric precancerous lesions and early gastric cancer to explore crucial molecules in intestinal-type gastric cancer tumorigenesis [J]. J Pathol , 2020 , 251 ( 2 ): 135 - 146 . DOI: 10.1002/path.5434 http://dx.doi.org/10.1002/path.5434 .
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621